473 related articles for article (PubMed ID: 19487219)
1. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
3. Screening for pulmonary arterial hypertension in patients with scleroderma--a New Zealand perspective.
Ghosh SK; Corkill MM; Hart HH; Ng KP
N Z Med J; 2014 Aug; 127(1400):30-8. PubMed ID: 25145365
[TBL] [Abstract][Full Text] [Related]
4. [Pulmonary arterial hypertension and systemic sclerosis].
Launay D; Humbert M; Hachulla E
Presse Med; 2006 Dec; 35(12 Pt 2):1929-37. PubMed ID: 17159719
[TBL] [Abstract][Full Text] [Related]
5. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
6. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
7. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
McLaughlin VV
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
[TBL] [Abstract][Full Text] [Related]
8. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
11. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
[TBL] [Abstract][Full Text] [Related]
12. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.
Clements PJ; Tan M; McLaughlin VV; Oudiz RJ; Tapson VF; Channick RN; Rubin LJ; Langer A;
Ann Rheum Dis; 2012 Feb; 71(2):249-52. PubMed ID: 21998119
[TBL] [Abstract][Full Text] [Related]
13. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
Beghetti M; Galiè N
J Am Coll Cardiol; 2009 Mar; 53(9):733-40. PubMed ID: 19245962
[TBL] [Abstract][Full Text] [Related]
14. Current pharmacological treatment of pulmonary arterial hypertension.
Steiropoulos P; Trakada G; Bouros D
Curr Clin Pharmacol; 2008 Jan; 3(1):11-9. PubMed ID: 18690874
[TBL] [Abstract][Full Text] [Related]
15. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
[TBL] [Abstract][Full Text] [Related]
16. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials.
Avouac J; Wipff J; Kahan A; Allanore Y
Ann Rheum Dis; 2008 Jun; 67(6):808-14. PubMed ID: 17901091
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
18. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
Beghetti M
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006
[TBL] [Abstract][Full Text] [Related]
19. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
Ahmadi-Simab K; Hellmich B; Gross WL
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
[TBL] [Abstract][Full Text] [Related]
20. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension.
Giannelli G; Iannone F; Marinosci F; Lapadula G; Antonaci S
Curr Med Res Opin; 2005 Mar; 21(3):327-32. PubMed ID: 15811199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
